![Christine Blumhardt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christine Blumhardt
Career history of Christine Blumhardt
Former positions of Christine Blumhardt
Companies | Position | Start | End |
---|---|---|---|
Somnus Therapeutics, Inc.
![]() Somnus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Somnus Therapeutics, Inc. operates as a pharmaceutical company. It develops therapeutics to address the need of insomnia patients. The company was founded by Gary C. Cupit in June 2007 is headquartered in Branchburg, NJ. | General Counsel | 2009-06-18 | - |
Smithkline Beecham Plc
![]() Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Corporate Officer/Principal | - | - |
Massachusetts College of Pharmacy & Health Science | Corporate Officer/Principal | - | - |
GSK PLC | Corporate Officer/Principal | - | - |
Wyeth Pharmaceuticals LLC
![]() Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | General Counsel | - | - |
Peptimmune, Inc.
![]() Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | General Counsel | 2005-05-09 | - |
Training of Christine Blumhardt
Temple University (Pennsylvania) | Undergraduate Degree |
The Pennsylvania State University | Undergraduate Degree |
University of Tennessee | Undergraduate Degree |
Statistics
International
United States | 8 |
United Kingdom | 3 |
Operational
General Counsel | 3 |
Corporate Officer/Principal | 3 |
Undergraduate Degree | 3 |
Sectoral
Health Technology | 6 |
Consumer Services | 5 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
GSK PLC | Health Technology |
Private companies | 4 |
---|---|
Smithkline Beecham Plc
![]() Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Health Technology |
Wyeth Pharmaceuticals LLC
![]() Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Peptimmune, Inc.
![]() Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Somnus Therapeutics, Inc.
![]() Somnus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Somnus Therapeutics, Inc. operates as a pharmaceutical company. It develops therapeutics to address the need of insomnia patients. The company was founded by Gary C. Cupit in June 2007 is headquartered in Branchburg, NJ. | Health Technology |
- Stock Market
- Insiders
- Christine Blumhardt
- Experience